According to Nazareth et al. [18], infliximab corrects the defective TNF production of Crohn’s disease macrophages, which seemed to depend upon the enrichment of CD16+ circulating monocytes (including non-classical CD14+CD16++ subset). This evidence concerns the gene CD14 and Crohn disease.